Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Talal Khader

Internal Medicine Southfield, MI Medical Doctor

NPI 1033314513 CMS profile 1399952

16001 W 9 Mile Rd, 4Th Fl Fisher Ctr, Southfield, MI 48075

Open in the dashboard

General payments

$4,622

181 records reported · program years 2019–2025

Research payments

$1,045

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$314,397 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Talal Khader of Southfield, MI is reported in the CMS Open Payments database as having received $4,622 across 181 general payments and $1,045 in research payments paid to them. Separately, studies naming them as principal investigator received $314,397 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,418 56
2024 General $668 24
2023 General $756 33
2023 Research $1,045 2
2022 General $798 35
2021 General $715 23
2020 General $120 6
2019 General $147 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Talal Khader
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Talal Khader were reported at $1,418. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Talal Khader Internal Medicine median Middle half National median
2019 $147 $159 $48–$570 $163
2020 $120 $119 $33–$402 $114
2021 $715 $135 $37–$521 $132
2022 $798 $141 $42–$496 $149
2023 $756 $149 $45–$519 $160
2024 $668 $154 $47–$537 $164
2025 $1,418 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,185 39 payments
  2. GlaxoSmithKline, LLC. $1,163 50 payments
  3. Aimmune Therapeutics, Inc. $263 3 payments
  4. Lilly USA, LLC $237 8 payments
  5. AbbVie, Inc. $216 12 payments
  6. AMAG Pharmaceuticals, Inc. $216 2 payments
  7. ITI, Inc. $193 19 payments
  8. Orexo US, Inc. $147 4 payments
  9. Ironwood Pharmaceuticals, Inc $135 7 payments
  10. Daiichi Sankyo Inc. $123 1 payment
  11. Other $745 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,565 180 payments
  2. Education $57 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $713 44 payments
  2. AIRSUPRA $291 3 payments
  3. ZENPEP $276 4 payments
  4. FERAHEME $216 2 payments
  5. MOUNJARO $183 5 payments
  6. CAPLYTA $166 18 payments
  7. Zubsolv $147 4 payments
  8. VRAYLAR $145 8 payments
  9. Linzess $135 7 payments
  10. INJECTAFER $123 1 payment
  11. Other $1,375 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,045 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 168 drugs

Part D claims

10,502

Median for Internal Medicine: 777

Drug cost

$849,059

Median for Internal Medicine: $73,373

Branded share of claims

30.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 166 $105,563
Jardiance Empagliflozin Brand 138 $97,420
Trulicity Dulaglutide Brand 78 $73,850
Eliquis Apixaban Brand 81 $66,155
Ozempic Semaglutide Brand 58 $61,044
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 201 $37,451
Mounjaro Tirzepatide Brand 32 $34,557
Januvia Sitagliptin Phosphate Brand 41 $30,959
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 48 $30,126
Xarelto Rivaroxaban Brand 35 $29,693

The 10 drugs with the highest cost, of 168 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$131,385

Of which drugs: $2,215

Medicare patients

285

Average age 67

Services billed

2,205

153 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 44%
Diabetes 41%
Depression 28%
Ischemic heart disease 27%
Chronic kidney disease 26%
COPD 26%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 24 24 $1,882
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 31 $27
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 44 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $145
$145 — —
XTANDI
  • Astellas Pharma US Inc $115
$115 — —
Linzess
  • Ironwood Pharmaceuticals, Inc $93
$93 35 —
BRIXADI
  • Braeburn Inc. $46
$46 11 —
VRAYLAR
  • AbbVie, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record